About Hemangio
Our mission is to build the space we needed when we were in the same position you are now.
We aim to be the bridge between you and the most valuable resources to assist you on your journey, building a supportive community to walk alongside you and empowering veterinary professionals to continue providing their best care for canine patients.
Where it all began
Our Impact
5MM
Committed
15
World’s Top Medical Experts as Advisors
100+
Dogs & their Families Supported
We’re proud to be a 501(c)3 nonprofit organization.
We are proud to be a 501(c)3 nonprofit organization, dedicated to making a difference in the lives of dogs and their families facing hemangiosarcoma. We are committed to driving awareness, providing educational resources, and supporting vital research initiatives. Through a community-oriented approach, we strive to improve the quality of life for dogs diagnosed with this aggressive form of cancer. Your support is invaluable in helping us achieve these goals.
Recent Updates
The Pain of Knowing: Coping with Anticipatory Grief
The flood of emotions that come with your dog's hemangiosarcoma diagnosis doesn’t come with any warnings. One of the first and most...
Can Your Anxiety Affect Your Dog?
Caring for a dog with hemangiosarcoma is tough. Here’s how your emotional health may be affecting theirs.
Canine Chemotherapy: Myths, Truths, and Everything In Between
There are many misconceptions and old beliefs that veterinarians and researchers are fighting to demystify.
Toxicity Profile of eBAT in Hemangiosarcoma
This study evaluates the safety and efficacy of eBAT in treating dogs with hemangiosarcoma, showing promising results with mild side effects and potential to prolong survival.
Pleiotropic Effects of Resveratrol on Cardiovascular Diseases in Dogs
This study explores how resveratrol supplementation may reduce chemotherapy-induced cardiac toxicity in dogs while enhancing anti-tumor effects in hemangiosarcoma.
Autologous Dendritic Cell Therapy in Stage II Hemangiosarcoma
The group that received full dendritic cell therapy had a median survival of 256 days, with a 29% one-year survival rate.